Abstract:Genome editing with CRISPR/Cas9 is a promising new approach for correcting or mitigating disease-causing mutations. Duchenne muscular dystrophy (DMD) is associated with lethal degeneration of cardiac and skeletal muscle caused by more than 3000 different mutations in the X-linked dystrophin gene ( DMD ). Most of these mutations are clustered in “hotspots.” There is a fortuitous correspondence between the eukaryotic splice acceptor and splice donor sequences and the protospacer adjacent motif sequences that govern prokaryotic CRISPR/Cas9 target gene recognition and cleavage. Taking advantage of this correspondence, we screened for optimal guide RNAs capable of introducing insertion/deletion (indel) mutations by nonhomologous end joining that abolish conserved RNA splice sites in 12 exons that potentially allow skipping of the most common mutant or out-of-frame DMD exons within or nearby mutational hotspots. We refer to the correction of DMD mutations by exon skipping as myoediting. In proof-of-concept studies, we performed myoediting in representative induced pluripotent stem cells from multiple patients with large deletions, point mutations, or duplications within the DMD gene and efficiently restored dystrophin protein expression in derivative cardiomyocytes. In three-dimensional engineered heart muscle (EHM), myoediting of DMD mutations restored dystrophin expression and the corresponding mechanical force of contraction. Correcting only a subset of cardiomyocytes (30 to 50%) was sufficient to rescue the mutant EHM phenotype to near-normal control levels. We conclude that abolishing conserved RNA splicing acceptor/donor sites and directing the splicing machinery to skip mutant or out-of-frame exons through myoediting allow correction of the cardiac abnormalities associated with DMD by eliminating the underlying genetic basis of the disease.

A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing

Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing

CRISPR-Cas9 Corrects Duchenne Muscular Dystrophy Exon 44 Deletion Mutations in Mice and Human Cells.

In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers

A Consolidated AAV System for Single-Cut CRISPR Correction of a Common Duchenne Muscular Dystrophy Mutation

Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model

CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice

CRISPR Correction of Duchenne Muscular Dystrophy.

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein

Toward the correction of muscular dystrophy by gene editing

Correction of Diverse Muscular Dystrophy Mutations in Human Engineered Heart Muscle by Single-Site Genome Editing

Efficient correction of Duchenne muscular dystrophy mutations by SpCas9 and dual gRNAs

Generation and characterisation of mouse models of Duchenne Muscular Dystrophy (DMD)

CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives

Long-term Maintenance of Dystrophin Expression and Resistance to Injury of Skeletal Muscle in Gene Edited DMD Mice.

In vivo gene editing in dystrophic mouse muscle and muscle stem cells

Single-Swap Editing for the Correction of Common Duchenne Muscular Dystrophy Mutations

Correction of human non-sense mutation via adenine base editing for Duchenne muscular dystrophy treatment in mouse

Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy

In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse